Literature DB >> 862758

Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.

A A Hakim.   

Abstract

Transplantable spontaneous mammary adenocarcinoma and sarcoma P 1798 cells were incubated with vibrio cholera neuraminidase (VCN), then fixed cells demonstrated ability to exclude trypan blue dye and to immunized animals and produce cytotoxic sera of high titers. The fixed neuramindase-treated tumor cells became non-oncogenic and protected the host against high doses of fresh untreated homologous tumors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862758     DOI: 10.1007/bf01922248

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  10 in total

1.  Immunogenicity of leukemia L1210 cells after neuraminidase treatment.

Authors:  J G Bekesi; G St Arneault; L Walter; J F Holland
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

2.  Comparative effect of viral and bacterial neuraminidase on the complement sensitivity of lymphoid cells.

Authors:  P K Ray; R L Simmons
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

3.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

4.  Differential release of sialic acid from normal and malignant cells by Vibrio cholerae neuraminidase or influenza virus neuraminidase.

Authors:  R K Ray; R L Simmons
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

5.  The serologic behaviour of neuraminidase-treated lymphoid cells. Alloantigenicity and complement sensitivity.

Authors:  P K Ray; H Gewurz; R L Simmons
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

6.  Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.

Authors:  R L Simmons; A Rios; G Lundgren; P K Ray; C F McKhann; G R Haywood
Journal:  Surgery       Date:  1971-07       Impact factor: 3.982

7.  Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.

Authors:  J G Bekesi; G St-Arneault; J F Holland
Journal:  Cancer Res       Date:  1971-12       Impact factor: 12.701

8.  Human tumor-specific antigens.

Authors:  I Hellström; G E Pierce; K E Hellström
Journal:  Surgery       Date:  1969-06       Impact factor: 3.982

9.  Mechanism of action of BCG vaccine on neoplastic proliferation and host immune responses.

Authors:  A A Hakim; N G Grand
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

10.  Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.

Authors:  R L Simmons; A Rios
Journal:  Science       Date:  1971-11-05       Impact factor: 47.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.